Vaxart Files Definitive Additional Materials
Ticker: VXRT · Form: DEFA14A · Filed: May 5, 2025 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | DEFA14A |
| Filed Date | May 5, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, sec-filing, company-history
TL;DR
Vaxart dropped more proxy docs, shareholders pay attention.
AI Summary
Vaxart, Inc. filed a Definitive Additional Materials (DEFA14A) on May 5, 2025. This filing relates to their proxy statement and is not a preliminary filing. The company, formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing indicates Vaxart is providing updated or additional information related to its proxy statement, which is crucial for shareholders to make informed voting decisions.
Risk Assessment
Risk Level: low — This is a routine filing for additional proxy materials and does not inherently signal new risks.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- Aviragen Therapeutics, Inc. (company) — Former Company Name
- Biota Pharmaceuticals, Inc. (company) — Former Company Name
- NABI BIOPHARMACEUTICALS (company) — Former Company Name
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, specifically 'Definitive Additional Materials'.
When was this filing made?
The filing was made on May 5, 2025.
What is Vaxart, Inc.'s primary business sector?
Vaxart, Inc. operates in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector.
What were some of Vaxart's previous company names?
Vaxart was formerly known as Aviragen Therapeutics, Inc., Biota Pharmaceuticals, Inc., and NABI BIOPHARMACEUTICALS.
Is this a preliminary proxy statement?
No, this is a Definitive Additional Materials filing, not a preliminary proxy statement.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 5, 2025 regarding Vaxart, Inc. (VXRT).